BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 20654581)

  • 1. The rGel/BLyS fusion toxin inhibits STAT3 signaling via down-regulation of interleukin-6 receptor in diffuse large B-cell lymphoma.
    Lyu MA; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Rosenblum MG
    Biochem Pharmacol; 2010 Nov; 80(9):1335-42. PubMed ID: 20654581
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The rGel/BLyS fusion toxin inhibits diffuse large B-cell lymphoma growth in vitro and in vivo.
    Lyu MA; Rai D; Ahn KS; Sung B; Cheung LH; Marks JW; Aggarwal BB; Aguiar RC; Gandhi V; Rosenblum MG
    Neoplasia; 2010 May; 12(5):366-75. PubMed ID: 20454508
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The rGel/BLyS fusion toxin specifically targets malignant B cells expressing the BLyS receptors BAFF-R, TACI, and BCMA.
    Lyu MA; Cheung LH; Hittelman WN; Marks JW; Aguiar RC; Rosenblum MG
    Mol Cancer Ther; 2007 Feb; 6(2):460-70. PubMed ID: 17267661
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The therapeutic effects of rGel/BLyS fusion toxin in in vitro and in vivo models of mantle cell lymphoma.
    Lyu MA; Pham LV; Sung B; Tamayo AT; Ahn KS; Hittelman WN; Cheung LH; Marks JW; Cho MJ; Ford RJ; Aggarwal BB; Rosenblum MG
    Biochem Pharmacol; 2012 Aug; 84(4):451-8. PubMed ID: 22687624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The growth factor fusion construct containing B-lymphocyte stimulator (BLyS) and the toxin rGel induces apoptosis specifically in BAFF-R-positive CLL cells.
    Nimmanapalli R; Lyu MA; Du M; Keating MJ; Rosenblum MG; Gandhi V
    Blood; 2007 Mar; 109(6):2557-64. PubMed ID: 17119117
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DCZ3301, a novel cytotoxic agent, inhibits proliferation in diffuse large B-cell lymphoma via the STAT3 pathway.
    Sun X; Li B; Xie B; Xu Z; Chang G; Tao Y; Zhang Y; Chang S; Wang Y; Yu D; Xie Y; Li T; Wang H; Chen G; Hu L; Hou J; Zhang Y; Xiao W; Gao L; Shi J; Zhu W
    Cell Death Dis; 2017 Oct; 8(10):e3111. PubMed ID: 29022919
    [TBL] [Abstract][Full Text] [Related]  

  • 7. SYK inhibition and response prediction in diffuse large B-cell lymphoma.
    Cheng S; Coffey G; Zhang XH; Shaknovich R; Song Z; Lu P; Pandey A; Melnick AM; Sinha U; Wang YL
    Blood; 2011 Dec; 118(24):6342-52. PubMed ID: 22025527
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cerdulatinib, a novel dual SYK/JAK kinase inhibitor, has broad anti-tumor activity in both ABC and GCB types of diffuse large B cell lymphoma.
    Ma J; Xing W; Coffey G; Dresser K; Lu K; Guo A; Raca G; Pandey A; Conley P; Yu H; Wang YL
    Oncotarget; 2015 Dec; 6(41):43881-96. PubMed ID: 26575169
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Honokiol inhibits signal transducer and activator of transcription-3 signaling, proliferation, and survival of hepatocellular carcinoma cells via the protein tyrosine phosphatase SHP-1.
    Rajendran P; Li F; Shanmugam MK; Vali S; Abbasi T; Kapoor S; Ahn KS; Kumar AP; Sethi G
    J Cell Physiol; 2012 May; 227(5):2184-95. PubMed ID: 21792937
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Rituximab inactivates signal transducer and activation of transcription 3 (STAT3) activity in B-non-Hodgkin's lymphoma through inhibition of the interleukin 10 autocrine/paracrine loop and results in down-regulation of Bcl-2 and sensitization to cytotoxic drugs.
    Alas S; Bonavida B
    Cancer Res; 2001 Jul; 61(13):5137-44. PubMed ID: 11431352
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fbw7 regulates apoptosis in activated B-cell like diffuse large B-cell lymphoma by targeting Stat3 for ubiquitylation and degradation.
    Yao S; Xu F; Chen Y; Ge Y; Zhang F; Huang H; Li L; Lin D; Luo X; Xu J; Luo D; Zhu X; Liu Y
    J Exp Clin Cancer Res; 2017 Jan; 36(1):10. PubMed ID: 28069035
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Restoration of shp1 expression by 5-AZA-2'-deoxycytidine is associated with downregulation of JAK3/STAT3 signaling in ALK-positive anaplastic large cell lymphoma.
    Han Y; Amin HM; Frantz C; Franko B; Lee J; Lin Q; Lai R
    Leukemia; 2006 Sep; 20(9):1602-9. PubMed ID: 16871283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective interleukin-1 receptor-associated kinase 4 inhibitors for the treatment of autoimmune disorders and lymphoid malignancy.
    Kelly PN; Romero DL; Yang Y; Shaffer AL; Chaudhary D; Robinson S; Miao W; Rui L; Westlin WF; Kapeller R; Staudt LM
    J Exp Med; 2015 Dec; 212(13):2189-201. PubMed ID: 26621451
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cooperative signaling through the signal transducer and activator of transcription 3 and nuclear factor-{kappa}B pathways in subtypes of diffuse large B-cell lymphoma.
    Lam LT; Wright G; Davis RE; Lenz G; Farinha P; Dang L; Chan JW; Rosenwald A; Gascoyne RD; Staudt LM
    Blood; 2008 Apr; 111(7):3701-13. PubMed ID: 18160665
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Blockade of HMGB1 signaling pathway by ethyl pyruvate inhibits tumor growth in diffuse large B-cell lymphoma.
    Zhang T; Guan XW; Gribben JG; Liu FT; Jia L
    Cell Death Dis; 2019 Apr; 10(5):330. PubMed ID: 30988279
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Biodistribution, pharmacokinetics, and nuclear imaging studies of 111In-labeled rGel/BLyS fusion toxin in SCID mice bearing B cell lymphoma.
    Wen X; Lyu MA; Zhang R; Lu W; Huang Q; Liang D; Rosenblum MG; Li C
    Mol Imaging Biol; 2011 Aug; 13(4):721-9. PubMed ID: 20686856
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hyperactivated STAT3 in ALK-positive diffuse large B-cell lymphoma with clathrin-ALK fusion.
    Momose S; Tamaru J; Kishi H; Mikata I; Mori M; Toyozumi Y; Itoyama S
    Hum Pathol; 2009 Jan; 40(1):75-82. PubMed ID: 18755494
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Selective inhibition of STAT3 induces apoptosis and G(1) cell cycle arrest in ALK-positive anaplastic large cell lymphoma.
    Amin HM; McDonnell TJ; Ma Y; Lin Q; Fujio Y; Kunisada K; Leventaki V; Das P; Rassidakis GZ; Cutler C; Medeiros LJ; Lai R
    Oncogene; 2004 Jul; 23(32):5426-34. PubMed ID: 15184887
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment of acute lymphoblastic leukemia with an rGel/BLyS fusion toxin.
    Parameswaran R; Yu M; Lyu MA; Lim M; Rosenblum MG; Groffen J; Heisterkamp N
    Leukemia; 2012 Aug; 26(8):1786-96. PubMed ID: 22373785
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Inhibition of constitutive STAT3 activity sensitizes resistant non-Hodgkin's lymphoma and multiple myeloma to chemotherapeutic drug-mediated apoptosis.
    Alas S; Bonavida B
    Clin Cancer Res; 2003 Jan; 9(1):316-26. PubMed ID: 12538484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.